Edition:
India

Sunesis Pharmaceuticals Inc (SNSS.OQ)

SNSS.OQ on NASDAQ Stock Exchange Capital Market

0.40USD
2:25am IST
Change (% chg)

$-0.01 (-2.39%)
Prev Close
$0.41
Open
$0.41
Day's High
$0.41
Day's Low
$0.40
Volume
138,664
Avg. Vol
124,161
52-wk High
$1.77
52-wk Low
$0.24

Latest Key Developments (Source: Significant Developments)

Sunesis Pharmaceuticals Says Qtrly Loss Per Share $0.09
Thursday, 8 Aug 2019 

Aug 7 (Reuters) - Sunesis Pharmaceuticals Inc ::SUNESIS PHARMACEUTICALS REPORTS SECOND QUARTER 2019 FINANCIAL RESULTS AND RECENT HIGHLIGHTS.SUNESIS PHARMACEUTICALS INC - QTRLY LOSS PER SHARE $0.09.  Full Article

Sunesis Pharmaceuticals Reports Fourth Quarter Loss Per Share Of $0.16
Friday, 8 Mar 2019 

March 7 (Reuters) - Sunesis Pharmaceuticals Inc ::SUNESIS PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL-YEAR 2018 FINANCIAL RESULTS AND RECENT HIGHLIGHTS.QTRLY LOSS PER SHARE $0.16.Q4 EARNINGS PER SHARE VIEW $-0.21 -- REFINITIV IBES DATA.  Full Article

Sunesis Announces Pricing Of $20 Mln Offering Of Securities
Friday, 18 Jan 2019 

Jan 17 (Reuters) - Sunesis Pharmaceuticals Inc ::SUNESIS ANNOUNCES PRICING OF $20 MILLION OFFERING OF SECURITIES.ANNOUNCED PRICING OF UNDERWRITTEN PUBLIC OFFERINGS OF 23 MILLION SHARES OF ITS COMMON STOCK AT $0.50.PRICING OF UNDERWRITTEN PUBLIC OFFERINGS OF 17,000 SHARES OF ITS NON-VOTING SERIES E CONVERTIBLE PREFERRED STOCK AT $500.SUNESIS EXPECTS TO RECEIVE COMBINED GROSS PROCEEDS OF APPROXIMATELY $20 MILLION FROM THESE OFFERINGS.  Full Article

Sunesis Pharmaceuticals Announces Proposed Public Offering Of Common Stock And Preferred Stock
Friday, 18 Jan 2019 

Jan 17 (Reuters) - Sunesis Pharmaceuticals Inc ::SUNESIS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK AND PREFERRED STOCK.  Full Article

Sunesis Pharmaceuticals Inc - Daniel Swisher Resigns As CEO Effective End Of 2017
Tuesday, 5 Dec 2017 

Dec 4 (Reuters) - Sunesis Pharmaceuticals Inc ::SUNESIS PHARMACEUTICALS INC - DANIEL SWISHER RESIGNS AS CEO EFFECTIVE END OF 2017.SUNESIS PHARMACEUTICALS INC - SWISHER TO REMAIN WITH SUNESIS AS A STRATEGIC ADVISOR.SUNESIS PHARMACEUTICALS INC - BOARD MEMBER DAYTON MISFELDT APPOINTED INTERIM CEO EFFECTIVE JANUARY 2018.  Full Article

Sunesis Pharmaceuticals Appoints William Quinn As CFO
Thursday, 30 Nov 2017 

Nov 30 (Reuters) - Sunesis Pharmaceuticals Inc ::SUNESIS PHARMACEUTICALS APPOINTS WILLIAM QUINN AS CHIEF FINANCIAL OFFICER AND SENIOR VICE PRESIDENT, FINANCE AND CORPORATE DEVELOPMENT.SUNESIS PHARMACEUTICALS INC - ‍WILLIAM QUINN MOST RECENTLY SERVING AS CEO AND CO-FOUNDER OF PRIVATE CANCER IMMUNOTHERAPY COMPANY BULLET BIOTECHNOLOGY​.  Full Article